Genetic testing has expanded considerably in its clinical applications over the past decade, and the range of tests available to patients and clinicians now covers a spectrum from targeted single-gene tests to comprehensive analyses of the full genetic code. Within that spectrum, two approaches are particularly relevant for the diagnosis of rare and inherited conditions: whole exome sequencing and whole genome sequencing. These two tests are often discussed together, sometimes used interchangeably in conversation, and frequently misunderstood in terms of what each one covers, what it costs, and when one is more appropriate than the other.
Understanding the distinction is practically useful for families navigating a diagnostic journey, for clinicians making referral decisions, and for anyone trying to make sense of a recommendation they have received without enough context to evaluate it.
What Each Test Actually Examines
The human genome contains approximately three billion base pairs of DNA. Of that total, a relatively small proportion, roughly one to two percent, makes up the exome, which is the collection of gene regions that contain the instructions for making proteins. Most of the genetic variants that cause known inherited diseases are located within this protein-coding region, which is why the exome became the focus of a targeted sequencing approach. A whole exome sequencing test reads these protein-coding regions in detail, identifies variants within them, and compares those variants against known databases of disease-associated genetic changes.
Whole genome sequencing reads the entire three billion base pairs rather than only the protein-coding fraction. This includes the exome but also the large non-coding regions of the genome, some of which are now understood to play regulatory roles in how genes are expressed, even if their function is less comprehensively characterized than the exome at present. The additional coverage of whole genome sequencing means it can in theory detect a broader range of variant types, including structural changes and variants in regions outside the exome, though the clinical interpretation of findings in non-coding regions remains more limited than for exonic variants.
The practical difference between the two tests for a patient seeking a diagnosis for a suspected genetic condition comes down to what is being looked for and what level of information is needed to answer the clinical question. For conditions where the responsible genes are likely to be among the known disease-causing genes in the exome, a whole exome sequencing test covers the relevant territory at lower cost and with a well-established interpretation framework. For situations where exome sequencing has not produced a diagnosis and broader coverage is warranted, whole genome sequencing is the logical next step.
Medgenome’s diagnostic services cover both approaches for rare and inherited disorder investigation, and the process for ordering a test, understanding the results, and accessing genetic counseling support is structured to make the clinical pathway as clear as possible for both referring clinicians and patients. The specifics of what the test covers and how results are reported are available through this page on whole exome sequencing test, which outlines the clinical applications and the ordering process.
For families thinking through the cost dimension of the investigation, the whole exome sequencing test price and how it compares across different testing approaches is part of the same page, which is a useful reference point when planning a diagnostic workup that may involve multiple steps.
When the Choice Between the Two Matters Clinically
The decision between exome and genome sequencing is not always straightforward and is typically one that benefits from a conversation with a genetic specialist rather than a self-directed choice. The clinical presentation, the suspected condition category, the family history, and what previous testing has been done all influence which approach is more likely to be informative for a specific patient.
One consideration that comes up more often than expected is the yield of the test, meaning the proportion of patients with a given clinical presentation who receive a diagnosis from the sequencing. For conditions with a well-characterized genetic basis, whole exome sequencing has a high diagnostic yield and is the most cost-effective starting point. For conditions where the genetic architecture is less well understood, or where previous targeted testing has not identified a cause, the broader coverage of whole genome sequencing may provide additional diagnostic opportunities.
The turnaround time between sample collection and results is another practical consideration that affects which test is chosen in specific clinical contexts. For a patient where a diagnosis is needed to guide urgent treatment decisions, the faster turnaround of a well-established exome test may be more relevant than the broader coverage of a genome test with a longer processing timeline.
Akash Sharma